Pipeline

Rytol Bioscience has 31 clinical candidates (chemical compositions) that it holds exclusive patented licenses too. With 5 lead targets under clinical development: Glioblastoma Multiforme, Epilepsy, and Acute Myelogenous Leukemia.

Rytol Bioscience is targeting the fastest growing oncology markets, with its lead candidate targeting glioma. With no existing therapy on the market that extends the life of a patient more than 1 year, Rytol Bioscience set out to improve the life expectancy of patients. With the glioma market having an expected annual growth rate of 8.8% from 2021 to 2028, and expected to reach 4.20 Billion (USD) by the end of 2028, it is one of the fastest growing markets in the oncology sector. Rytol Bioscience is led by an experienced management team, stemming from the academic and oncology field, with proven capabilities in identifying, acquiring and progressing clinical targets to the next stage.